https://www.selleckchem.com/pr....oducts/Etopophos.htm
Our objective was to examine differences in cytokine/chemokine response in chronic hepatitis B(CH patients to understand the immune mechanism of HBsAg loss (functional cure) during antiviral therapy. We used an unbiased machine learning strategy to unravel the immune pathways in CHB nuclet)side analogue-treated patients who achieved HBsAg loss with peg-interferon-α(peg-IFN-α) add-on or switch treatment in a randomised clinical trial. Cytokines/chemokines from plasma were compared between those with/without HBsAg loss, at baseline,
Like
Comment
Share
